Vir Biotechnology Inc(VIR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 29 at 4:00 PM ET (Korea 10/30 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.86 | Insider Own | 20.77% | Shs Outstand | 169.2M | Perf Week | 12.66% |
| Market Cap | 1.99B | Forward P/E | - | EPS next Y | -43.86% | Insider Trans | -0.07% | Shs Float | 134.1M | Perf Month | 5.1% |
| Enterprise Value | 1.55B | PEG | - | EPS next Q | -0.74 | Inst Own | 68.07% | Short Float | 12.11% | Perf Quarter | 35.68% |
| Income | -0.25B | P/S | 6.56 | EPS this Y | 43.95% | Inst Trans | 4.87% | Short Ratio | 8.5 | Perf Half Y | 15.03% |
| Sales | 0.30B | P/B | 2.02 | EPS next 5Y | 12.69% | ROA | -20.91% | Short Interest | 16.24M | Perf YTD | 94.86% |
| Book/sh | 5.81 | P/C | 3.72 | EPS past 3/5Y | - -4.76% | ROE | -26.08% | 52W High | -2.08% ($12.00) | Perf Year | 98.82% |
| Cash/sh | 3.16 | P/FCF | - | Sales past 3/5Y | -65.12% -2.14% | ROIC | -23.6% | 52W Low | 144.03% ($4.82) | Perf 3Y | 51.42% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 53.66% | Gross Margin | 96.2% | Volatility(W/M) | 6.08% 6.2% | Perf 5Y | -68.86% |
| Dividend TTM | - | EV/Sales | 5.1 | Sales Y/Y TTM | 1495.93% | Oper. Margin | -92.16% | ATR (14) | 0.63 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 6.04 | EPS Q/Q | 159.17% | Profit Margin | -83% | RSI (14) | 59.8 | Recom | 1.1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.04 | Sales Q/Q | 19582.54% | SMA20 | 6.6% ($11.02) | Beta | 1.71 | Target Price | $21 |
| Payout | - | Debt/Eq | 0.09 | Earnings | 2026/11/4 | SMA50 | 7.78% ($10.9) | Rel Volume | 0.74 | Prev Close | $11.93 |
| Employees | 367 | LT Debt/Eq | 0.09 | EPS/Sales Surpr. | 41.31% 75.85% | SMA200 | 23.7% ($9.5) | Avg Volume(3M) | 1.91M | Price | $11.75 |
| IPO | 2019/10/11 | Option/Short | Yes/Yes | Trades | 10277 | Volume | 1,421,824 | Change | -1.51% |
🧬 Vir Biotechnology (VIR) is a clinical-stage biopharmaceutical company that harnesses the immune system to target serious infectious diseases and cancer. Building on its antibody discovery and engineering capabilities and its proprietary Xtend masking platform, the company is developing therapeutic candidates for chronic hepatitis D and solid tumors. Its clinical-driven structure places greater emphasis on pipeline progress than on revenue.
Over the past 1 year, on the higher side
2% below its 1-year high.
Traded less than usual. That is 74% of its average volume.
Next earnings report: November 4
5 days to go.
VIR has a sound balance sheet but weak earning power
Of every $100 in sales, $92.16 is lost.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +44.0% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $656. Peers typically go for $1,217. Compared with its own 1-year average, it is 88% pricier now.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -68.9%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 68.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
IDNA iShares Genomics Immunology and Healthcare ETF 0.01% 
GNOM Global X Genomics & Biotechnology ETF 0.01% 
BBC Virtus Biotech Clinical Trials ETF <0.01% 
PSCH Invesco S&P SmallCap Health Care ETF <0.01% 
XBI State Street SPDR S&P Biotech ETF <0.01% Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
USCL iShares Climate Conscious & Transition MSCI USA ETF 2.8B 
KLMT Invesco MSCI Global Climate 500 ETF 1.6B 
PWRD TCW Transform Systems ETF 1.4B 
CRBN iShares Low Carbon Optimized MSCI ACWI ETF 1.2B 
LCTU iShares U.S. Carbon Transition Readiness Aware Active ETF 1.2B It ranks #106 of 594 in the industry
Based on market cap of $2B.
SRPT#104 Sarepta Therapeutics Inc $2B PER - 
GENB#105 Generate Biomedicines Inc $2B PER - VIR#106 Vir Biotechnology Inc $2B PER - 
ADRX#107 ADARx Pharmaceuticals Inc $2B PER - 
TRVI#108 Trevi Therapeutics Inc $2B PER - 
FAQ
What kind of company is VIR?
VIR belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of VIR?
The market cap of VIR is approximately $2.0B, ranking 2,068 within its sector.
What is the 52-week high and low for VIR?
VIR has recorded a 52-week high of $12.00 and a low of $4.82.
